Institutional members access full text with Ovid®

Share this article on:

Trans-catheter mitral valve implantation for mitral regurgitation: clinical case description and literature review.

Romeo, Francesco; Cammalleri, Valeria; Ruvolo, Giovanni; Quadri, Arshad; De Vico, Pasquale; Muscoli, Saverio; Marchei, Massimo; Meloni, Sabrina; Conti, Fabio; Ussia, Gian Paolo
Journal of Cardiovascular Medicine: Post Author Corrections: November 7, 2015
doi: 10.2459/JCM.0000000000000328
Narrative Review: PDF Only

Trans-catheter mitral valve implantation (TMVI) is actually the most attractive technique for treating patients with severe mitral regurgitation, who are denied surgical therapy. Recently, trans-catheter implantation of aortic biological prosthesis in mitral position has been done in compassionate cases, and very few experiences of TMVI in native non-calcified valves have been recently reported in very-high-risk patients, mainly with functional mitral regurgitation.

Here, we report our case of TMVI using the second-generation CardiAQ prostheisis (CardiAQ Valve Technologies, Irvine, California, USA), reviewing the current state of the art.

Copyright (C) 2015 Wolters Kluwer Health, Inc. All rights reserved.